scineurophadev - SciNeuro Pharmaceuticals

Steven Wong

Senior VP, Corporate Strategy and Business Development

Steven is a seasoned business development professional who brings 15 years of experience and has executed over $20 billion in aggregate deal value. He has worked at large-cap pharmaceutical companies and at biotechs across various therapeutic areas. Prior to SciNeuro, he held business development, strategy, and finance roles of increasing responsibility at Clover Biopharmaceuticals, AMAG Pharmaceuticals, Radius Health, Shire, and Novartis. Steven began his career as an investment banker and was most recently in Bank of America Merrill Lynch’s global healthcare group where he provided M&A advisory and capital raise services for biopharmaceutical clients. Steven received his B.A. in Physics from U.C. Berkeley and an M.B.A. from Indiana University.

SNP614

Leucine-rich repeat kinase 2(LRRK2) is a multifunctional protein with GTPase & kinase activities. LRRK2 gene mutations are associated with increased activities of LRRK2 protein, conferring elevated risk for Parkinson’s disease (PD). SNP614 is a chemically modified antisense oligonucleotide (ASO) efficiently downregulates LRRK2 mRNA thereby lowering its levels and activities linked to PD development and progression. ASO treatment enables a disease-modifying therapy and is superior to current standard of care (SoC) symptomatic approaches.

SNP201

Alpha-synuclein is a major component of Lewy bodies, a pathological hallmark of synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). SNP201 is a high affinity alpha-synuclein antibody, binding preferentially to aggregated forms of alpha-synuclein known to be pathogenic. Superior binding affinity and epitope recognition enable a favorable target engagement to achieve better clinical efficacy.

SNP318

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) is an enzyme that hydrolyzes oxidized phospholipids typically on low-density lipoprotein (LDL) to yield lysophosphatidylcholine (lysoPC), a potent proinflammatory factor in both CNS and periphery. LysoPC induces vascular inflammation, which leads to damages in blood vessels in the brain including blood-brain barrier (BBB). SNP318 is a CNS-penetrant inhibitor of Lp-PLA2 with the potential to repair BBB, thereby restoring vascular health and improving cognition in dementias such as Alzheimer’s disease (AD).

SNP210

Cytoplasmic Transactive response DNA binding protein of 43 kDa (TDP-43) forms toxic aggregates featuring C-terminal phosphorylation and correlating with neurodegeneration. Reduction of extracellular TDP-43 protects neurons from TDP-43 induced pathology and death. SNP210 is a human autoantibody isolated from patient with high affinity of disease-variant of TDP-43. Targeted disease indications include amyotrophic lateral sclerosis (ALS) and certain forms of frontotemporal dementia (FTD).

Author: scineurophadev